Headquartered in South San Francisco, CA Fiscal year ends December NASDAQ: ORIC oricpharma.com
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance in oncology. The company's pipeline includes two clinical-stage product candidates: rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit being developed for prostate cancer and currently in a global Phase 3 registrational trial (Himalayas-1) for metastatic castration-resistant prostate cancer; and enozertinib, a brain-penetrant inhibitor targeting EGFR exon 20 insertion mutations and EGFR atypical mutations being developed for non-small cell lung cancer (NSCLC) in Phase 1b trials. ORIC generates no product revenue and funds operations through equity financings. The company trades on Nasdaq under the ticker ORIC. Updated
Wall Street is drawing fresh lines across the large-cap biopharma landscape. Jefferies initiated coverage on Gilead Sciences Inc. (NASDAQ:GILD | GILD Price Prediction) with a Buy rating and a $180 price target,…
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance in oncology.
The Wall Street consensus 12-month price target for ORIC is $21.64.
